We are live on ! Find out more
5VM

5AM Venture Management Portfolio holdings

AUM $360M
1-Year Est. Return 345.76%
This Fund
S&P 500
This Quarter Est. Return
+38.38%
1 Year Est. Return
+345.76%
3 Year Est. Return
+491.51%
5 Year Est. Return
+330.26%
10 Year Est. Return
–
AUM
$273M
AUM Growth
+$12.9M
Cap. Flow
-$47.5M
Cap. Flow %
-17.38%
Top 10 Hldgs %
69.92%
Holding
29
New
–
Increased
1
Reduced
4
Closed
4

Top Buys

1
CAMP icon
CAMP4 Therapeutics
CAMP
+$5.45M

Top Sells

1
DNTH icon
Dianthus Therapeutics
DNTH
+$15.8M
2
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$13.3M
3
VOR icon
Vor Biopharma
VOR
+$10.3M
4
VKTX icon
Viking Therapeutics
VKTX
+$5.02M
5
SCPH
scPharmaceuticals
SCPH
+$4.57M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SKYE icon
1
Skye Bioscience
SKYE
$22.1M
$38M 13.94%
9,681,763
-231,405
-2% -$874K
TRDA icon
2
Entrada Therapeutics
TRDA
$267M
$24.7M 9.04%
4,256,379
-52,000
-1% -$304K
PHVS icon
3
Pharvaris
PHVS
$2.35B
$19.9M 7.29%
797,600
– –
CAMP icon
4
CAMP4 Therapeutics
CAMP
$203M
$17.6M 6.45%
5,869,091
+2,941,176
+100% +$5.45M
CNTA
5
DELISTED
Centessa Pharmaceuticals
CNTA
$16.5M 6.05%
680,945
-150,000
-18% -$2.67M
VRDN icon
6
Viridian Therapeutics
VRDN
$1.99B
$15.9M 5.82%
736,595
– –
ELVN icon
7
Enliven Therapeutics
ELVN
$3.63B
$15.8M 5.79%
772,477
– –
EYPT icon
8
EyePoint Inc
EYPT
$1.09B
$15M 5.48%
1,050,000
– –
DNTH icon
9
Dianthus Therapeutics
DNTH
$5.21B
$14.4M 5.26%
365,053
-619,672
-63% -$15.8M
TYRA icon
10
Tyra Biosciences
TYRA
$1.88B
$13.1M 4.81%
939,298
– –
CLDX icon
11
Celldex Therapeutics
CLDX
$2.78B
$12.9M 4.71%
497,270
– –
ERAS icon
12
Erasca
ERAS
$6.6B
$11.8M 4.32%
5,405,404
– –
PRAX icon
13
Praxis Precision Medicines
PRAX
$8.59B
$9.01M 3.3%
170,000
– –
GHRS icon
14
GH Research
GHRS
$2B
$8.19M 3%
572,665
– –
TECX
15
Tectonic Therapeutic
TECX
$578M
$8.03M 2.94%
511,660
– –
BHVN icon
16
Biohaven
BHVN
$2.13B
$7.19M 2.63%
478,972
– –
ARTV
17
Artiva Biotherapeutics
ARTV
$439M
$6.75M 2.47%
2,353,304
– –
SRZN icon
18
Surrozen
SRZN
$241M
$3.99M 1.46%
310,000
– –
TARA icon
19
Protara Therapeutics
TARA
$229M
$3.48M 1.27%
800,000
– –
ALEC icon
20
Alector
ALEC
$163M
$2.95M 1.08%
995,841
– –
SLN
21
Silence Therapeutics
SLN
$516M
$2.47M 0.91%
476,200
– –
ADVM
22
DELISTED
Adverum Biotechnologies
ADVM
$2.45M 0.9%
541,666
– –
RLYB icon
23
Rallybio
RLYB
$84.7M
$1.81M 0.66%
453,841
– –
ZNTL icon
24
Zentalis Pharmaceuticals
ZNTL
$325M
$740K 0.27%
490,000
– –
MRSN
25
DELISTED
Mersana Therapeutics
MRSN
$405K 0.15%
52,200
– –
1
2

Similar funds

LSC
Logan Stone Capital Chicago, Illinois $360M AUM 9.71% 1-Year Est. Return
BWM
BNC Wealth Management Beaverton, Oregon $360M AUM 49.82% 1-Year Est. Return
LC
Legacy CG Plano, Texas $360M AUM 17.55% 1-Year Est. Return
WIP
WealthCare Investment Partners Portsmouth, Rhode Island $360M AUM 19.98% 1-Year Est. Return
RA
RR Advisors Dallas, Texas $360M AUM 28.52% 1-Year Est. Return
SWM
SK Wealth Management Providence, Rhode Island $360M AUM 14.81% 1-Year Est. Return
PWM
Proathlete Wealth Management Boca Raton, Florida $361M AUM 17.13% 1-Year Est. Return
NC
Naman Capital Sao Paulo, Brazil $360M AUM 27.43% 1-Year Est. Return

5AM Venture Management's Q3 2025 Portfolio in Review

As of Q3 2025, 5AM Venture Management held 29 positions worth $273M, up 5% from $260M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

5AM Venture Management withdrew a net $47.5M in Q3 2025, closing 4 positions and reducing 4 holdings. Its most notable exit was MoonLake Immunotherapeutics, an estimated $13.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, 5AM Venture Management added an estimated $5.45M to CAMP4 Therapeutics.

  • 5AM Venture Management added most to CAMP4 Therapeutics in Q3 2025, an estimated $5.45M increase.
  • 5AM Venture Management's biggest Q3 2025 reduction was Dianthus Therapeutics, cutting an estimated $15.8M.
  • 5AM Venture Management fully exited MoonLake Immunotherapeutics in Q3 2025, selling an estimated $13.3M.
  • 5AM Venture Management's ten largest holdings make up 70% of its $273M portfolio in Q3 2025.
  • 5AM Venture Management opened 0 new positions and closed 4 in Q3 2025.
  • 5AM Venture Management's portfolio value rose 5% quarter-over-quarter to $273M.

Based on 5AM Venture Management's 13F filing for Q3 2025, filed 14 Nov 2025.